Dr. Abribat has a proven track record of developing innovative treatments for rare diseases, achieving three successful biotech/company exits He is a seasoned scientific and operational leader, having ...
Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20 th annual WORLDSymposium™ Four posters with baseline data from the natural history (PRONTO) study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback